Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
COREG · 2 trials · 1 indication
Bioequivalence based on Cmax
Bioequivalence based on AUC0-inf
Bioequivalence based on AUC0-t
| Arm | Type | Description |
|---|---|---|
| Carvedilol | EXPERIMENTAL | Carvedilol 25 mg Tablet (test) dosed in first period followed by Coreg® 25 mg Tablet (reference) dosed in second period |
| Coreg® | ACTIVE_COMPARATOR | Coreg® 25 mg Tablet (reference) dosed in first period followed by Carvedilol 25 mg Tablet (test) dosed in second period |
| Name | Type | Description |
|---|---|---|
| Carvedilol 25 mg tablets | DRUG | 1 x 25 mg |
| COREG® 25 mg tablets | DRUG | 1 x 25 mg |
Inclusion Criteria: * Sex: Male of Female; similar proportions of each preferred. * Age: At least 18 years. * Weight: Minimum of 120 pounds and a BMI (body mass index) of less than 30. Exclusion Criteria: * Subjects not complying with the above inclusion criteria must be excluded from the study. ...
COREG is a small molecule drug being developed by Teva Pharmaceutical Industries Limited (TEVA). It is currently in Phase 1 clinical development for use in healthy subjects. The drug is being studied in two completed clinical trials with a total enrollment of 60 participants.
COREG is being studied for use in healthy subjects. It is currently in Phase 1 clinical development, with two completed trials that enrolled healthy adult volunteers. The drug is not yet approved for any medical condition and remains investigational.
COREG is being developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. The company is conducting Phase 1 clinical trials of the drug in healthy subjects in the United States.
COREG is in Phase 1 clinical development. It has completed two Phase 1 trials, both of which enrolled healthy adult subjects. The drug is investigational and has not been approved by regulatory authorities.
COREG has been studied in two completed Phase 1 clinical trials: NCT00834795, which enrolled 36 fasted healthy subjects, and NCT00834873, which enrolled 24 fed healthy subjects. Both trials were conducted in the United States with participants aged 18 years and older.
COREG is a brand name for the drug carvedilol. The clinical trials for COREG, NCT00834795 and NCT00834873, are titled as studies of carvedilol 25 mg in healthy adult subjects, indicating that COREG and carvedilol refer to the same medication.